WHAT THE STUDY ACTUALLY SAYS

A single dose of caffeine at birth did not prevent kidney injury after asphyxia

In a double-blind trial of 78 newborns of at least 35 weeks with birth asphyxia, one intravenous dose of caffeine left the rate of acute kidney injury essentially unchanged against placebo.

Acute kidney injury incidence by groupCaffeine citrate: 28.2%; Normal saline: 35.9%0%20%40%Caffeine citrate28.2%Normal saline35.9%
Acute kidney injury incidence by group
GroupValue (%)
Caffeine citrate28.2
Normal saline35.9
Acute kidney injury incidence by group Newborns of at least 35 weeks with perinatal asphyxia randomised to a single intravenous dose of caffeine citrate or normal saline; counts were 11 of 39 and 14 of 39. Source: Pediatric Nephrology

Babies who are starved of oxygen around the time of birth — perinatal asphyxia — are at risk of injury to several organs, and the kidneys are among the most vulnerable. In premature infants, the stimulant caffeine has been linked to a lower rate of acute kidney injury, which raised a reasonable hypothesis: might a dose of caffeine given at birth protect the kidneys of asphyxiated newborns too? A small, carefully designed trial has now tested that question, and found that it did not [s1].

What the trial did

The study was a parallel-group, double-blind, randomised placebo-controlled trial [s1]. It enrolled 78 neonates of at least 35 weeks' gestation who had perinatal asphyxia defined by the criteria of the US National Institute of Child Health and Human Development [s1]. Within two hours of birth, infants were randomly assigned to receive either a single intravenous dose of caffeine citrate at 20 mg/kg (39 babies) or normal saline as placebo (39 babies) [s1]. The trial was registered prospectively with the Clinical Trials Registry of India as CTRI/2024/08/073008 [s2].

The primary outcome was the incidence of acute kidney injury [s1]. The researchers also tracked a wide set of secondary measures: the severity of kidney injury, serial serum creatinine and urine output, serum cystatin-C, the incidence and severity of hypoxic-ischaemic encephalopathy, blood flow in the anterior cerebral and renal arteries, cerebral and renal tissue oxygenation, in-hospital complications, caffeine-related adverse events, and a standardised neurological examination at discharge [s1]. The analysis followed intention-to-treat principles [s1].

What it found

Acute kidney injury was common in both groups, and caffeine did not reduce it. Injury occurred in 11 of 39 infants (28.2%) given caffeine and in 14 of 39 (35.9%) given saline, with a P value of 0.467 — a difference well within the range expected by chance in a trial this size [s1]. The severity of injury, serial creatinine values, urine output and cystatin-C levels were all comparable between the groups [s1].

The secondary outcomes moved in step with the primary one — which is to say, they did not move. The incidence and severity of hypoxic-ischaemic encephalopathy, blood flow in the anterior cerebral and renal arteries, cerebral and renal tissue oxygenation, in-hospital complications including mortality, and neurological examination scores at discharge were all similar between caffeine and placebo [s1]. On the safety side, the caffeine group's complications included tachycardia and low blood potassium (hypokalaemia) [s1].

How to read it

This is a clean null result, and its main value is in closing off a plausible but unproven idea before it spreads into practice. The extrapolation from premature infants — where caffeine is already standard for other reasons — to term and near-term babies with asphyxia was reasonable, but reasoning by analogy is not evidence, and this trial supplied the evidence [s1].

The most important limit is size. With 39 infants per group, the trial could only detect a fairly large effect, so a genuine but modest benefit cannot be ruled out from these numbers alone [s1]. The study also tested a single dose given once; it says nothing about whether repeated dosing, a different dose, or caffeine given alongside therapeutic hypothermia — the cooling treatment used for moderate-to-severe asphyxia — might behave differently. The authors themselves flag exactly these open questions [s1]. And the safety signals, though minor, are a reminder that a stimulant is not a free intervention in a sick newborn [s1].

What to watch

The authors call for further research on dose, frequency and the specific setting of neonates undergoing therapeutic hypothermia to settle whether caffeine has any reno-protective role after asphyxia [s1]. Until a larger trial reports, the honest summary is narrow: a single intravenous dose of caffeine at birth did not lower the rate or severity of acute kidney injury, did not improve the neurological measures tracked, and carried its own minor cardiac and metabolic effects [s1].

This article describes a single small trial and is not medical advice. Decisions about newborn care belong with the clinicians responsible for the baby.

Sources

  1. Caffeine for prevention of acute kidney injury in neonates with perinatal asphyxia: a randomized placebo-controlled trial — Pediatric Nephrology , November 13, 2026
  2. Caffeine for prevention of acute kidney injury in neonates with perinatal asphyxia (CTRI/2024/08/073008) — Clinical Trials Registry - India , August 28, 2024

More on

Related coverage